Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers—results of a dose escalation trial

BACKGROUND: Certain disadvantages of the standard hematopoietic stem and progenitor cell (HSPC) mobilizing agent G-CSF fuel the quest for alternatives. We herein report results of a Phase I dose escalation trial comparing mobilization with a peptidic CXCR4 antagonist POL6326 (balixafortide) vs. G-CS...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Transl Med
Autores principales: Karpova, Darja, Bräuninger, Susanne, Wiercinska, Eliza, Krämer, Ariane, Stock, Belinda, Graff, Jochen, Martin, Hans, Wach, Achim, Escot, Christophe, Douglas, Garry, Romagnoli, Barbara, Chevalier, Eric, Dembowski, Klaus, Hooftman, Leon, Bonig, Halvard
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5209880/
https://ncbi.nlm.nih.gov/pubmed/28049490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-1107-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares